Long-Term Outcome After Adoptive Immunotherapy With Natural Killer Cells: Alloreactive NK Cell Dose Still Matters

Frontiers in Immunology

Andrea Bontadini¹  Elisa Dan³  Jacopo Nanni³  Letizia Zannoni³  Darina Ocadlikova³  Gianluca Cristiano³  Barbara Sinigaglia³  Michele Cavo³  Chiara Sartor³  Gabriella Chirumbolo³  Russell E. Lewis⁴  Andrea Velardi⁵  Loredana Ruggeri⁵  Sara Ciardelli⁵  Elena Urbani⁵  Antonio Curti⁶  Cristina Papayannidis⁶  Simonetta Rizzi⁶  Francesca Bonifazi⁶  Sarah Parisi⁶  Stefania Paolini⁶  Mario Arpinati⁶  Roberto M. Lemoli⁷  Valeria Giudice⁸  Giovanni Marconi⁹  Giovanni Martinelli⁹ 

[1] Blood Transfusion Department, Santa Maria degli Angeli Hospital, Pordenone, Italy;Clinic of Hematology, Department of Internal Medicine (DiMI), University of Genoa, Genoa, Italy;Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, Bologna, Italy;Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy;Division of Hematology and Clinical Immunology, Department of Medicine, University of Perugia, Ospedale Santa Maria della Misericordia, Perugia, Italy;IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia “Seràgnoli”, Bologna, Italy;IRCCS Policlinico S. Martino, Genoa, Italy;Immunohematology Service and Blood Bank, University Hospital S.Orsola-Malpighi, Bologna, Italy;Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy;

关键词: acute myeloid leukemia;    natural killer cells;    adoptive immune therapies;    alloreactivity;    cell dose;   

DOI  :  10.3389/fimmu.2021.804988

来源: DOAJ

【 摘 要 】

Recently, many reports were published supporting the clinical use of adoptively transferred natural killer (NK) cells as a therapeutic tool against cancer, including acute myeloid leukemia (AML). Our group demonstrated promising clinical response using adoptive immunotherapy with donor-derived alloreactive KIR-ligand-mismatched NK cells in AML patients. Moreover, the antileukemic effect was correlated with the dose of infused alloreactive NK cells (“functional NK cell dose”). Herein, we update the results of our previous study on a cohort of adult AML patients (median age at enrollment 64) in first morphological complete remission (CR), not eligible for allogeneic stem cell transplantation. After an extended median follow-up of 55.5 months, 8/16 evaluable patients (50%) are still off-therapy and alive disease-free. Overall survival (OS) and disease-free survival (DFS) are related with the dose of infused alloreactive NK cells (≥2 × 105/kg).

【 授权许可】

Unknown